drugset / Trial / NCT05726851
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants
RandomizedSequentialQuadruple-blindBasic science
Summary
The primary purpose of the study is to evaluate the safety and tolerability of single intravenous (IV) infusions of E2025 in healthy adult participants.
Timeline
- Start
- 2023-02-06
- Primary completion
- 2024-01-30
- Completion
- 2024-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | E2025 | Unknown | — | Intravenous |
Indications
No indication recorded.